ARTICLE | Company News

Galmed surges on NASH news

September 24, 2014 2:05 AM UTC

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) jumped $2.45 (38%) to $8.93 on Tuesday after FDA granted Fast Track designation to Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH).

Galmed plans to begin a Phase IIb trial of the fatty acid bile-acid conjugate (FABAC) in 240 obese and insulin resistant patients with NASH by year end. No drugs are currently approved to treat NASH. ...